We found that myoCAFs, but not other CAF subsets, associate with poor prognosis in NMIBC patients, consistent with findings in MIBC.48,49 Mezheyeuski et al. tested CAF-associated markers in BLCA, finding associations with high-grade NMIBC and identifying fibroblast activation protein (FAP) as a predictor of poor outcome, although not when separating Ta, T1, and T2–4.50 Interestingly, aSMA was statistically associated with worse prognosis only for T1 tumors, aligning with our findings. This evidence concerns the gene FAP and bladder transitional cell carcinoma.